Selective-intra-arterial radionuclide therapy (SIRT) using radiolabeled microspheres are being widely employed for the delivery of therapeutic radioisotope to liver cancers by exploiting the dual blood supply to liver. It delivers the therapeutic radiations to tumor and spares the healthy liver. Several radiolabeled microspheres formulations, labelled with Y, are commercially available. However, high-cost leads to unaffordability for several patients. Re-based therapy seems affordable due to commercial availability of W/Re generator that have long shelf-life of more than 6 months. To provide affordable solution, the microsphere cold kit with quick and facile methodology for Re radiolabeling has been developed. The microsphere cold kit has been characterized for their physicochemical properties. The Quality Control (QC) tests were also performed for clinical application. The feasibility studies were performed to study distribution and retention of Re microspheres in tumor. The results demonstrated that the developed cold kit enables facile and quick radiolabeling with Re. Re microspheres showed good retention in tumor and found suitable for SIRT.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.apradiso.2022.110423 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!